

Indoco Q3FY19 Revenues at Rs. 248 Crores

Mumbai, 23rd **January 2019:** Indoco Remedies posted revenues of ₹ 248.0 crores during the Third quarter of FY 2018-19, as against ₹ 274.2 crores, for the same quarter last year. The Company posted a profit of ₹ 5.3 crores, as against profit of ₹ 22.7 crores, for the same quarter last year.

Commenting on the 3rd quarter results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "We are in the process of Regulatory resolutions due to which, our sales continue to get affected. We expect the business performance to start looking up from the next financial year".

For the guarter ended Dec'18, the financials are as under:

(₹ in Crores)

| Particulars | Oct'18 - Dec'18 | Oct'17 - Dec'17 |
|-------------------------------|-----------------|-----------------|
| Net Revenues | 248.0 | 274.2 |
| EBIDTA | 24.8 | 43.2 |
| Operating Profit | 15.8 | 38.2 |
| Profit After Tax | 5.3 | 22.7 |
| EPS (Face value ₹ 2/-) | 0.58 | 2.46 |
| (Not annualized) | 0.36 | 2.40 |

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 161 million Company, employs over 5500 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around

3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Tuspel Plus, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com / corpcom@indoco.com